GLP-1 Breakthroughs and Dr. Coy’s Sugars Are Two Sides of the Same Coin

by | Aug 12, 2025 | News

A recent article published by MDLinx has neurologists abuzz: GLP-1 receptor agonists—originally developed to manage type 2 diabetes and obesity—are showing significant promise in reducing the risk and progression of Alzheimer’s disease. These findings add to a growing body of research connecting metabolic dysfunction with cognitive decline. The reason? They improve how the body and brain handles sugar, reduce inflammation, and protect nerve cells.

But while GLP-1 drugs are a remarkable therapeutic development, they are not the only tool in our arsenal. Just as important as treatment is prevention—and that’s where Dr. Coy’s sugars and the Intelligent Sugar concept come in.

A Shared Goal: Protecting the Brain Through Metabolic Health

GLP-1 RAs (receptor agonists), work by improving insulin sensitivity, mimicking the natural GLP-1 hormone produced in the gut, lowering blood glucose levels, reducing systemic inflammation, and enhancing glucose uptake in the brain.

These mechanisms make them valuable not only in diabetes management but increasingly in the early stages of neurodegeneration, especially Alzheimer’s disease [1].

At the same time, Dr. Coy’s sugars—such as isomaltulose, tagatose, and galactose—offer a nutritional route to the same outcome. These sugars digest more slowly, reduce glucose spikes, do not feed inflammatory anaerobic metabolism, and support more stable cellular energy. Unlike conventional sugars, they help stabilize blood sugar and insulin levels, easing the pressure on metabolic systems and supporting long-term brain health [2].

A Unified Strategy for Brain Health

As Alzheimer’s is increasingly referred to as “type 3 diabetes,” it’s becoming clearer that blood sugar, insulin signalling, and inflammation play fundamental roles in both brain aging and disease.

Together, they form a comprehensive strategy:

  • Dr. Coy’s sugars help prevent metabolic imbalances;
  • GLP-1 RAs are used to treat imbalances that are already present.

Because one prevents – one treats the imbalance.

Prevention Meets Precision: The Intelligent Sugar Approach

The Intelligent Sugar approach, based on the research of molecular biologist Dr. Johannes Coy, is rooted in decades of investigation into the TKTL1 gene, sugar metabolism, and disease progression. Rather than cutting out sugar entirely, the approach focuses on using specific sugars that fuel the brain and body without overstimulating insulin or driving inflammation.

These include:

  • Galactose, which fuels the hippocampus without the blood sugar surge [3].
  • Isomaltulose, which digests slowly and improves memory-related glucose supply [4].
  • Tagatose, which helps lower postprandial blood glucose and supports gut and liver health [5].

These sugars also don’t contribute to tooth decay, making them beneficial for children and adults alike. Together, they form a preventive nutraceutical strategy: one that supports cognitive, metabolic, and even cellular resilience through daily nutrition.

Complementary Tools, Not Competing Ones

GLP-1 therapies and Dr. Coy’s sugars address different stages of the same issue and should be seen as complementary, not conflicting. In fact, they are two sides of the same coin:

Dr. Coy’s Sugars GLP-1 Receptor Agonists
Preventive Therapeutic
Daily nutritional use Metabolic and neuroprotective medication
Stabilise glucose Lower glucose actively
Anti-inflammatory effect through diet Anti-inflammatory effect pharmalogically
Supports healthy individuals Targets insulin-resistant, obese or diabetic individuals

 

In the future, optimal brain health will require both nutritional intelligence and therapeutic innovation. Prevention and treatment are not rivals—they’re allies in the fight for longevity, clarity, and cognitive resilience.

 

 

References

  1. MDLinx. “Neurologists are buzzing about the latest GLP-1 Alzheimer’s breakthroughs—here’s what they’re saying.” July 2025. https://www.mdlinx.com/article/neurologists-are-buzzing-about-the-latest-glp-1-alzheimers-breakthroughs-heres-what-they-re-saying/2rrLhJCXlKPGRjt5EcTJES
  2. Coy, J. “The Intelligent Sugar.” Austin Macauley Publishers, 2024.
  3. Fernandes, M.F., et al. “Brain glucose and galactose metabolism: role in Alzheimer’s disease.” Frontiers in Aging Neuroscience, 2018.
  4. Holub, I., et al. “Metabolic effects of isomaltulose compared with other sugars: results of randomized controlled trials.” American Journal of Clinical Nutrition, 2010.
  5. Lu, Y., Levin, G.V., and Donner, T.W. “Tagatose, a new antidiabetic and obesity control drug.” Diabetes, Obesity and Metabolism, 2008.